For more information about Cleveland Clinic Innovations’ therapeutics and diagnostics technologies, please visit
Cleveland Clinic researchers have developed a first-in-class drug that shows remarkable promise in treating Alzheimer’s disease and cognitive disorders by targeting a specific brain receptor in a novel way.
The groundbreaking research, led by principal investigator, Dianne Perez, PhD, focuses on the α1A-Adrenergic Receptors (ARs). These proteins are well known to play crucial roles in blood pressure regulation but also mediate neuroprotection and cognitive function.
To learn more about Dr. Perez, please visit
If you liked the video hit like and subscribe for more!
#clevelandclinic #innovations #alzheimersresearch
source